Bristol-Myers Squibb vs Sanofi

Bristol-Myers Squibb (BMY), health care, and Sanofi (SNY), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Bristol-Myers Squibb is worth $124.7B on the stock market and Sanofi $115.1B: Bristol-Myers Squibb is valued at 8% more. Bristol-Myers Squibb trades at 13.5 times earnings and Sanofi at 23.9. Over the past year Bristol-Myers Squibb's share price has moved +33.7% and Sanofi's -4.48%.

Key facts

Bristol-Myers Squibb market value
$124.7B
Sanofi market value
$115.1B
Bristol-Myers Squibb P/E
13.5
Sanofi P/E
23.9
Bristol-Myers Squibb revenue
$48.2BFY to 2025-12-31
Sanofi revenue
$48.4BFY to 2025-12-31
Superinvestors holding both
2

Market values as of .

Bristol-Myers Squibb vs Sanofi: every measure side by side
Measure Bristol-Myers Squibb Sanofi
SectorHealth CareHealth Care
Country United States France
Fiscal year ends2025-12-312025-12-31
Size
Market cap$124.7Bhigher$115.1Blower
Revenue$48.2Blower$48.4Bhigher
Earnings$7.1Blower$8.7Bhigher
Employees32,500lower74,846higher
Total assets$90Blower$140.7Bhigher
Valuation
P/E13.5lower23.9higher
P/S2.6higher2.4lower
P/B5.3—
Dividend yield4.00%—
Profitability
Operating margin—14.5%
Balance sheet
Net assets$18.5Blower$79.2Bhigher
Total liabilities$71.5Bhigher$61.1Blower
Total debt$45.1Bhigher$20.8Blower
Cash on hand$10.2Bhigher$8.5Blower
Price change
Today-3.07%lower-0.92%higher
1 year+33.7%higher-4.48%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Bristol-Myers Squibb / Sanofi). Who owns BMY · Who owns SNY

Further comparisons

Learn

Questions and answers

Which is bigger, Bristol-Myers Squibb or Sanofi?

By market value, Bristol-Myers Squibb is the larger: $124.7B against $115.1B for Sanofi. By revenue in its latest fiscal year, Sanofi is the larger: $48.4B against $48.2B for Bristol-Myers Squibb.

Which has the higher P/E ratio?

Sanofi: 23.9, against 13.5 for Bristol-Myers Squibb. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has more debt?

Bristol-Myers Squibb: $45.1B, against $20.8B for Sanofi. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Bristol-Myers Squibb and Sanofi?

In their latest 13F filings, Richard Pzena and Sarah Ketterer hold both.

Cite this page

Funkfolio, “Bristol-Myers Squibb vs Sanofi”, data as of 17 November 2026. https://funkfolio.com/compare/bmy-vs-sny

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.